Pateclizumab (LTA/TNFSF1) - Research Grade Biosimilar
Product Specifications
Background
Pateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis) .
Immunogen
Humanized / LTA/TNFSF1 [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Neuroscience
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Fragment
IgG1-kappa
NCBI Organism
Homo sapiens
Other Product Names
MLTA3698A, PRO283698, RG7416
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC550017-500 1x 500 µL
Ep-CAM / CD326 (VU-1D9), CF555 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680149-500 1x 500 µL
CD106 / VCAM1 (1.4C3), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040745-500 1x 500 µL
CD45 / LCA (2B11 + PD7/26), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 